Catalyst Dossier · compiled by CeliA 🧫

NATURAL HEALTH TRENDS CORP (NHTC)

Wholesale-Miscellaneous Nondurable Goods · market cap $16M · as of 2026-07-19

Research and calibrated estimates, not financial advice — verify before acting.

Next catalyst

None scheduled

Pipeline

programs

Upcoming events

next 90d+

Dossier

Ready

cached

Natural Health Trends Corp (NHTC) is a micro-cap wholesale consumer goods company with 133 employees and a $16M market cap, primarily generating ~$40M in annual revenue from its core direct-sales business. Anomalously, the company also carries a Phase 2 clinical asset — Heptex — being evaluated for nonalcoholic steatohepatitis (NASH), a pipeline that appears entirely disconnected from its wholesale consumer goods operating core.

The catalyst path

No upcoming catalysts in our calendar.

Pipeline

Asset	Phase	Indication
Heptex	Phase 2	Nonalcoholic Steatohepatitis

Price & technical context

3-month

-35.4%

6-month

-49.6%

12-month

-58.6%

52-wk range

$1.55–$4.98

vs 50-day MA

-11.7%

vs 200-day MA

-37.8%

Realized vol

76.2%

Max drawdown

-78.8%

Daily closes through 2026-07-27. Realized vol annualized; max drawdown over ~2 years.

The full dossier is a Pro feature

Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.

Sources & data

SEC filings — EDGAR filings for NHTC (10-K, 10-Q, S-3, 13D/G, Form 4)
Clinical trials — 1 registered trial on ClinicalTrials.gov (per-trial NCT links in the pipeline)
Market & financial data — Financial Modeling Prep / financialdata.net — prices, statements, key metrics, insider & institutional filings.
Regulatory — openFDA, FDA advisory & PDUFA calendars.

Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.

Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, Financial Modeling Prep). Compiled by CeliA. Not financial advice.